Undiagnosed tuberculosis among HIV clinic attendees: Association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 2, 2012, Pages

  Kufa, Tendesayi ^a   Mngomezulu, Victor ^b   Charalambous, Salome ^a   Hanifa, Yasmeen ^a   Fielding, Katherine ^c   Grant, Alison D ^c   Wada, Nikolas ^d   Chaisson, Richard E ^d   Churchyard, Gavin J ^a,b,c   Gounder, Celine R ^c  

^a AURUM INSTITUTE   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; Case finding; Epidemiology; HIV; Screening; Tuberculosis

Indexed keywords

ANTIVIRUS AGENT; HEMOGLOBIN; ISONIAZID;

ADULT; ARTICLE; ASPIRATION BIOPSY; BLOOD CULTURE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH CARE PERSONNEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; SOUTH AFRICA; SPUTUM CULTURE; SPUTUM SMEAR; THORAX RADIOGRAPHY; TUBERCULOSIS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BACTERIOLOGICAL TECHNIQUES; BIOPSY, FINE-NEEDLE; CHEMOPREVENTION; FEMALE; HIV INFECTIONS; HUMANS; INFECTION CONTROL; ISONIAZID; LATENT TUBERCULOSIS; LYMPH NODES; MALE; PREVALENCE; RADIOGRAPHY, THORACIC; SOUTH AFRICA;

EID: 84862152782     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318251ae0b     Document Type: Article

References (30)

1. World Health Organization. Global Tuberculosis Control Report. Geneva, Switzerland: World Health Organization; 2010.
2. Organisation WH. Tuberculosis country profiles 2011. Available at: http://www.who.int/tb/country/data/profiles/en/index.html. Accessed April 8, 2011.
3. van Asten L, Langendam M, Zangerle R, et al. Tuberculosis risk varies with the duration of HIV infection: a prospective study of European drugusers with known date of HIV seroconversion. AIDS. 2003;17:1201-1208. (Pubitemid 36675363)
4. Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis. 2005;191:150-158. (Pubitemid 40096371)
5. Glynn JR, Murray J, Bester A, et al. Effects of duration of HIV infection and secondary tuberculosis transmission on tuberculosis incidence in the South African gold mines. AIDS. 2008;22:1859-1867.
6. World Health Organization. Priority Research Questions for Tuberculosis/ Human Immunodeficiency Virus (TB/HIV) in HIV-Prevalent and Resource-Limited Settings. Geneva, Switzerland: World Health Organization; 2010.
7. World Health Organization. Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource Constrained Settings. Geneva, Switzerland: World Health Organization; 2011.
8. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23:631-636.
9. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21: 1441-1448. (Pubitemid 46988004)
10. Jones JL, Hanson DL, Dworkin MS, et al. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis. 2000;4:1026-1031.
11. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS. 2000;14:1985-1991.
12. Dheda K, Lampe FC, Johnson MA, et al. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis. 2004;190:1670-1676. (Pubitemid 39411018)
13. Lawn SD, Harries AD, Williams BG, et al. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis. 2011;15:571-581.
14. Houlihan CF, Mutevedzi PC, Lessells RJ, et al. The tuberculosis challenge in a rural South African HIV programme. BMC Infect Dis. 2010; 10:23.
15. Lawn SD, Myer L, Edwards D, et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009;23:1717-1725.
16. Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis. 2010;51:823-829.
17. Lawn SD, Kranzer K, Edwards DJ, et al. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS. 2010;24:1323-1328.
18. Lawn SD, Myer L, Bekker LG, et al. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20:1605-1612. (Pubitemid 44162402)
19. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS. 2007;21:713-719. (Pubitemid 46568628)
20. Gounder CR, Kufa T, Wada NI, et al. Diagnostic accuracy of a urine lipoarabinomannan enzyme-linked immunosorbent assay for screening ambulatory HIV-infected persons for tuberculosis. J Acquir Immune Defic Syndr. 2011;58:219-223.
21. National Department of Health South Africa. National Antiretroviral Treatment Guidelines. Cape Town, South Africa: National Department of Health South Africa; 2004.
22. Den Boon S, Bateman ED, Enarson DA, et al. Development and evaluation of a new chest radiograph reading and recording system for epidemiological surveys of tuberculosis and lung disease. Int J Tuberc Lung Dis. 2005;9:1088-1096. (Pubitemid 41433798)
23. Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med. 2009;30:685-699; viii.
24. Middelkoop K, Bekker LG, Myer L, et al. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med. 2010;182: 1080-1085.
25. Ngowi BJ, Mfinanga SG, Bruun JN, et al. Pulmonary tuberculosis among people living with HIV/AIDS attending care and treatment in rural northern Tanzania. BMC Public Health. 2008;8:341.
26. Rajasekaran S, Raja K, Jeyaseelan L, et al. Post-HAART tuberculosis in adults and adolescents with HIV in India: incidence, clinical and immunological profile. Indian J Tuberc. 2009;56:69-76.
27. Grant AD, Bansi L, Ainsworth J, et al. Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? AIDS. 2009;23:2507-2515.
28. Manabe YC, Breen R, Perti T, et al. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis. 2009;199:437-444.
29. Statistics South Africa. Republic of South Africa. Millenium Development Goals, Country Report 2010. Pretoria, South Africa: Statistics South Africa; 2010.
30. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010;15(suppl 1):1-15.